Health System

Current phase 3 studies investigative novel, preventative approaches.

Investigational oral MET kinase inhibitor from Merck.

The age indication for some influenza vaccines has been expanded.

New changes are making it more difficult for generics and biosimilars to compete on formularies.

Technicians, clerks, even front-end cashiers are taking on new responsibilities.

Oral kinase inhibitor for SSc-ILD.

First generic specialty injections approved for Novadoz Pharmaceuticals. 

Number of reported cases hightest since 1992.

Though decreasing, initiatives and awareness will generate more revenue.

New results contradict HHS and FDA plans.

Cariprazine demonstrated greater improvement on the MADRS.

Grant-funded program to bring more opportunities for safe disposal.

Operational efficiencies, patient-centered care, and outcomes will get a boost.

A cure and a bargain?

Studies emphasize importance of shingles vaccinations for high-risk populations.

The second most common cause of atraumatic peripheral facial paralysis.

New pleuromutilin antibiotic IV and oral tablets.

Sexual harassment can come from both coworkers and patients. 

First new drug approval for the condition in nearly a decade. 

How can we protect the health of the millions of people who protect our own?

Pharmacogenetic testing, contraceptives, and more!

Medication errors cost the U.S. healthcare system $21 billion annually.

"The real problem to be solved is “Why do patients struggle to buy their prescriptions?” writes Frisch. 

2019 cases greater than five-year trend.

Kinase inhibitor oral capsules.

Survey indicates need for greater pharmacist presence. 

How to handle controlled substances and medication safely.

Dispensing robots began rolling out to retail and ambulatory care pharmacies in the 1990s.